Sydney, Australia 19 October 2021 C-BOBCAT breast cancer trial of Clarity’s SAR-Bombesin product closes for recruitment. The diagnostic program with 64Cu SAR-Bombesin generated evidence of the utility and potential superiority in some patient subgroups compared to conventional imaging (e.g. 99mTc bone scan, 18F FDG). The high uptake and strong product retention visualised by PET imaging…
30 September 2021 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, and Evergreen Theragnostics, Inc. (“Evergreen”), a radiopharmaceutical contract manufacturer, are pleased to announce that the companies have entered into a Targeted Copper Theranostics (TCTs) manufacturing agreement for Clarity’s US clinical trials.…
22 September 2021 Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or the “Company”), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, is pleased to announce that it is now a member and will hold a Board position on the Council on Radionuclides and Radiopharmaceuticals, Inc (CORAR), a trade association…
Sydney, Australia 25 August 2021 Clarity Pharmaceuticals lists on the ASX today under code CU6 after raising $92.0 million at $1.40 per share, equating to an indicative market capitalisation of approximately $358.6million (on an undiluted basis) at the Offer price. Clarity is an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing…
Sydney, Australia 25 August 2021 – Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or the “Company”), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, is pleased to announce that the first US patient has been dosed with 64Cu SAR-bisPSMA in the dosimetry phase of the SECuRE clinical trial (NCT04868604)1…
Sydney, Australia, 25 August 2021 – Clarity Pharmaceuticals was featured in the Australian Financial Review, Australian daily newspaper covering the latest business and economic affairs of Australia and the world. The article discusses Clarity’s ASX debut, its key investors and the company’s pipeline of products in development. Read the full article here: https://www.afr.com/companies/healthcare-and-fitness/clarity-pharma-charges-ahead-on-asx-debut-20210824-p58lev
Sydney, Australia, 21 July 2021 – Clarity Pharmaceuticals was featured in the Australian Financial Review, Australian daily newspaper covering the latest business and economic affairs of Australia and the world. The article discusses Clarity, our history, clinical trials, technology and the initial public offering on the Australian Securities Exchange. Read the full article here: https://www.afr.com/companies/healthcare-and-fitness/clarity-pharmaceuticals-to-hit-asx-in-august-20210720-p58b98
Sydney, Australia, 12 July 2021 – Clarity Pharmaceuticals was featured in the Australian Financial Review, Street Talk, the leading source of breaking news in Australia’s capital markets with live updates throughout the trading day. The article discusses the terms of Clarity’s initial public offering on the Australian Securities Exchange. Read the full article here: https://www.afr.com/street-talk/terms-out-for-clarity-s-358m-ipo-20210712-p588tj
Sydney, Australia, 8 July 2021 – Clarity Pharmaceuticals was featured in the Australian, Australia’s national broadsheet newspaper published by News Corp Australia since 14 July 1964. The article discusses Clarity’s initial public offering on the Australian Securities Exchange. Read the full article here: https://www.theaustralian.com.au/business/dataroom/clarity-pharmaceuticals-embarks-on-cornerstone-process-for-ipo/news-story/b2824850cb8686e039e68aecb9fafca2
Sydney, Australia, 8 July 2021 – Clarity Pharmaceuticals was featured in the Australian Financial Review, Street Talk, the leading source of breaking news in Australia’s capital markets with live updates throughout the trading day. The article discusses Clarity’s initial public offering on the Australian Securities Exchange and option agreement with China Grand Pharmaceuticals and Healthcare.…